COMPARTIVE ANIMAL CORE

比较动物核心

• 批准号: 8516645
• 负责人: Cheryl A London
• 金额: $ 23.33万
• 依托单位: RESEARCH INST NATIONWIDE CHILDREN'S HOSP
• 依托单位国家: 美国
• 财政年份: 2013
• 资助国家: 美国
• 起止时间: 2013-06-05 至 2018-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8516645
• 关键词: Adverse effects; Adverse event; Aftercare; Anatomy; Animal Model; Animals; Antineoplastic Agents; Biological Markers; Canis familiaris; Childhood; Clinical; Clinical Trials; Comparative Pathology; Development; Diagnosis; Disease; Drug Kinetics; Evaluation; Future; Genetic Engineering; Goals; Housing; Human; In Vitro; Individual; Instruction; London; Malignant Neoplasms; Maximum Tolerated Dose; Medical Oncologist; Modeling; Mus; Normal tissue morphology; Oncology; PTPRC gene; Pathologist; Pathology; Patients; Pharmacodynamics; Phenotype; Process; Program Research Project Grants; Progression-Free Survivals; Research Personnel; Resource Sharing; Sampling; Specimen; Standardization; Testing; Therapeutic; Tissue Banking; Tissue Banks; Tissue Sample; Toxic effect; Tumor Tissue; Veterinary Medicine; Veterinary Pathology; Work; Xenograft procedure; anti-cancer therapeutic; college; comparative; design; drug candidate; drug development; drug discovery; experience; inhibitor/antagonist; mouse model; novel; novel therapeutic intervention; novel therapeutics; osteosarcoma; patient population; research and development; response; sarcoma; small molecule; success; therapeutic target; tool; tumor

The overall goal ofthe comparative animal core is to support the development and use ofthe animal models employed within this Program Project Grant. The guiding principals for the comparative animal core are efficient planning and utilization of tissue and tumor samples, standardization of processing and diagnoses, and continued development of the canine spontaneous tumor animal model. This Core is housed and coordinated in the Department of Veterinary Biosciences in the College of Veterinary Medicine at OSU and includes individuals with expertise in comparative pathology, tissue banking, and clinical trial development and execution. Dr. Cheryl London, the proposed Core Director, is a Board Certified Veterinary Medical Oncologist with extensive expertise in cancer drug development including validating novel targets, identifying appropriate small molecules for target inhibition, and testing these compounds in relevant canine cancers with the goal of providing critical information that can assist in the human drug development process. Drs. Krista La Perie and Brad Bolon, Co-Investigators, are Board Certified in Veterinary Anatomic Pathology and are experts in the field of comparative pathology, particularly with respect to mouse models of cancer and evaluation of novel therapeutics in these models. The primary objective of this Core is to assist investigators in determining both the toxicities and activity associated with novel therapeutic approaches in mouse models of sarcoma, to identify candidate drugs/treatments that are likely to have success in the clinical setting, and to evaluate these treatments in dogs with spontaneous sarcomas as a prelude to future human clinical trials. As such, the specific aims of this Core are to: 1) Provide a standardized histopathologic evaluation of sarcomas generated in mouse models of disease following treatment with various targeted therapeutics; 2) Identify adverse effects associated with treatment of mice with novel therapeutics. 3) Provide high quality normal and tumor tissue samples from dogs with spontaneous sarcomas; and 4) Assess the adverse event profile and biologic activity of a novel STATS inhibitor (LY5) in normal dogs and dogs with spontaneous osteosarcoma.

比较动物核心的总体目标是支持本计划项目拨款中使用的动物模型的开发和使用。比较动物核心的指导原则是组织和肿瘤样本的有效规划和利用、处理和诊断的标准化以及犬自发性肿瘤动物模型的持续开发。该核心由俄勒冈州立大学兽医学院兽医生物科学系负责安置和协调，成员包括在比较病理学、组织库以及临床试验开发和执行方面具有专业知识的人员。拟议的核心主任 Cheryl London 博士是一位经过委员会认证的兽医肿瘤学家，在癌症药物开发方面拥有丰富的专业知识，包括验证新靶标、识别用于靶标抑制的适当小分子以及在相关犬类癌症中测试这些化合物，目的是提供有助于人类药物开发过程的关键信息。博士。共同研究员 Krista La Perie 和 Brad Bolon 获得了兽医解剖病理学委员会认证，是比较病理学领域的专家，特别是在小鼠癌症模型和这些模型中新疗法的评估方面。该核心的主要目标是帮助研究人员确定与肉瘤小鼠模型中的新治疗方法相关的毒性和活性，确定可能在临床环境中取得成功的候选药物/治疗方法，并评估这些治疗方法在患有自发性肉瘤的狗身上进行研究，作为未来人类临床试验的前奏。因此，该核心的具体目标是： 1) 对用各种靶向疗法治疗后的小鼠疾病模型中产生的肉瘤提供标准化的组织病理学评估； 2) 确定与用新疗法治疗小鼠相关的副作用。 3）提供来自患有自发性肉瘤的犬的高质量正常和肿瘤组织样本； 4) 评估新型 STATS 抑制剂 (LY5) 在正常犬和患有自发性骨肉瘤的犬中的不良事件概况和生物活性。